Cisplatin-mediated activation of extracellular signal-regulated kinases 1/2 (ERK1/2) by inhibition of ERK1/2 phosphatases

Journal of Neurochemistry

Volumn 106, Issue 5, 2008, Pages 2056-2067

  Gozdz, Agata ^a,b   Vashishta, Aruna ^a   Kalita, Katarzyna ^a,b   Szatmari, Erzsebet ^a   Zheng, Jing Juan ^a   Tamiya, Shigeo ^a   Delamere, Nicholas A ^c   Hetman, Michal ^a,d  

^a University of Louisville School of Medicine   (United States)

^b NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

DNA damage; Mitogen activated protein kinase; NMDA receptor; Phosphatases; Transcription

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CISPLATIN; DIZOCILPINE; DUAL SPECIFICITY PHOSPHATASE 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHATASE; VACCINIA RELATED KINASE 3;

ARTICLE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; ANIMALS, NEWBORN; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CISPLATIN; DUAL SPECIFICITY PHOSPHATASE 6; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASES; NERVE DEGENERATION; NEURONS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; TRANS-ACTIVATION (GENETICS);

RATTUS;

EID: 49549100904     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05550.x     Document Type: Article

References (42)

1. Adams J. P. Sweatt J. D. (2002) Molecular psychology: roles for the ERK MAP kinase cascade in memory. Annu. Rev. Pharmacol. Toxicol. 42, 135 163.
2. Apostol B. L., Illes K., Pallos J. et al. (2006) Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum. Mol. Genet. 15, 273 285.
3. Arany I., Megyesi J. K., Kaneto H., Price P. M. Safirstein R. L. (2004) Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am. J. Physiol. Renal Physiol. 287, F543 F549.
4. Benhar M., Engelberg D. Levitzki A. (2002) Cisplatin-induced activation of the EGF receptor. Oncogene 21, 8723 8731.
5. Bhalla U. S., Ram P. T. Iyengar R. (2002) MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 297, 1018 1023.
6. Boisvert F. M., Hendzel M. J. Bazett-Jones D. P. (2000) Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA. J. Cell Biol. 148, 283 292.
7. Brunet A., Roux D., Lenormand P., Dowd S., Keyse S. Pouyssegur J. (1999) Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 18, 664 674.
8. Cha J. H. (2000) Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 23, 387 392.
9. Choi Y. S., Lin S. L., Lee B., Kurup P., Cho H. Y., Naegele J. R., Lombroso P. J. Obrietan K. (2007) Status epilepticus-induced somatostatinergic hilar interneuron degeneration is regulated by striatal enriched protein tyrosine phosphatase. J. Neurosci. 27, 2999 3009.
10. Chu C. T., Levinthal D. J., Kulich S. M., Chalovich E. M. DeFranco D. B. (2004) Oxidative neuronal injury. The dark side of ERK1/2. Eur. J. Biochem. 271, 2060 2066.
11. Cullinane C., Mazur S. J., Essigmann J. M., Phillips D. R. Bohr V. A. (1999) Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage. Biochemistry 38, 6204 6212.
12. Denu J. M. Tanner K. G. (1998) Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 37, 5633 5642.
13. Ding Q., Dimayuga E., Markesbery W. R. Keller J. N. (2006) Proteasome inhibition induces reversible impairments in protein synthesis. FASEB J. 20, 1055 1063.
14. Ekerot M., Stavridis M. P., Delavaine L., Mitchell M. P., Staples C., Owens D. M., Keenan I. D., Dickinson R. J., Storey K. G. Keyse S. M. (2008) Negative feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter. Biochem. J. 6, ahead of print online publication.
15. Gauthier S., Reisberg B., Zaudig M. et al. (2006) Mild cognitive impairment. Lancet 367, 1262 1270.
16. Gozdz A., Habas A., Jaworski J., Zielinska M., Albrecht J., Chlystun M., Jalili A. Hetman M. (2003) Role of N-methyl-d-aspartate receptors in the neuroprotective activation of extracellular signal-regulated kinase 1/2 by cisplatin. J. Biol. Chem. 278, 43663 43671.
17. Habas A., Kharebava G., Szatmari E. Hetman M. (2006) NMDA neuroprotection against a phosphatidylinositol-3 kinase inhibitor LY294002 by NR2B-mediated suppression of glycogen synthase kinase-3beta-induced apoptosis. J. Neurochem. 96, 335 348.
18. Hetman M. Gozdz A. (2004) Role of extracellular signal regulated kinases 1 and 2 in neuronal survival. Eur. J. Biochem. 271, 2050 2055.
19. Ho Y., Logue E., Callaway C. W. DeFranco D. B. (2007) Different mechanisms account for extracellular-signal regulated kinase activation in distinct brain regions following global ischemia and reperfusion. Neuroscience 145, 248 255.
20. Kang T. H. Kim K. T. (2006) Negative regulation of ERK activity by VRK3-mediated activation of VHR phosphatase. Nat. Cell Biol. 8, 863 869.
21. Kim S. H., Markham J. A., Weiler I. J. Greenough W. T. (2008) Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome. Proc. Natl Acad. Sci. USA 10, ahead of print online publication.
22. Kondoh K. Nishida E. (2007) Regulation of MAP kinases by MAP kinase phosphatases. Biochim. Biophys. Acta 1773, 1227 1237.
23. Kruman I. I. Schwartz E. I. (2008) DNA damage response and neuroprotection. Front. Biosci. 13, 2504 2515.
24. Levinthal D. J. DeFranco D. B. (2005) Reversible oxidation of ERK-directed protein phosphatases drives oxidative toxicity in neurons. J. Biol. Chem. 280, 5875 5883.
25. Lu T., Pan Y., Kao S. Y., Li C., Kohane I., Chan J. Yankner B. A. (2004) Gene regulation and DNA damage in the ageing human brain. Nature 429, 883 891.
26. McDonald E. S., Randon K. R., Knight A. Windebank A. J. (2005) Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol. Dis. 18, 305 313.
27. Muda M., Boschert U., Dickinson R., Martinou J. C., Martinou I., Camps M., Schlegel W. Arkinstall S. (1996) MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. J. Biol. Chem. 271, 4319 4326.
28. Niedernhofer L. J., Garinis G. A., Raams A. et al. (2006) A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 444, 1038 1043.
29. Okafor M., Tamiya S. Delamere N. A. (2003) Sodium-calcium exchange influences the response to endothelin-1 in lens epithelium. Cell Calcium 34, 231 240.
30. Paul S., Nairn A. C., Wang P. Lombroso P. J. (2003) NMDA-mediated activation of the tyrosine phosphatase STEP regulates the duration of ERK signaling. Nat. Neurosci. 6, 34 42.
31. Qian Z., Gilbert M. Kandel E. R. (1994) Temporal and spatial regulation of the expression of BAD2, a MAP kinase phosphatase during seizure kindling and long-term potentiation. Learn. Mem. 1, 180 188.
32. Rybak L. P., Whitworth C. A., Mukherjea D. Ramkumar V. (2007) Mechanisms of cisplatin-induced ototoxicity and prevention. Hear. Res. 226, 157 167.
33. Saxena M. Mustelin T. (2000) Extracellular signals and scores of phosphatases: all roads lead to MAP kinase. Semin. Immunol. 12, 387 396.
34. Schramek H., Schumacher M. Pfaller W. (1996) Sustained ERK-2 activation in rat glomerular mesangial cells: differential regulation by protein phosphatases. Am. J. Physiol. 271, F423 F432.
35. Stanciu M. DeFranco D. B. (2002) Prolonged nuclear retention of activated extracellular signal-regulated protein kinase promotes cell death generated by oxidative toxicity or proteasome inhibition in a neuronal cell line. J. Biol. Chem. 277, 4010 4017.
36. Szatmari E., Habas A., Yang P., Zheng J. J., Hagg T. Hetman M. (2005) A positive feedback loop between glycogen synthase kinase 3beta and protein phosphatase 1 after stimulation of NR2B NMDA receptors in forebrain neurons. J. Biol. Chem. 280, 37526 37535.
37. Tolar M., Keller J. N., Chan S., Mattson M. P., Marques M. A. Crutcher K. A. (1999) Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity. J. Neurosci. 19, 7100 7110.
38. Treiber D. K., Zhai X., Jantzen H. M. Essigmann J. M. (1994) Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc. Natl Acad. Sci. USA 91, 5672 5676.
39. Tymianski M., Charlton M. P., Carlen P. L. Tator C. H. (1993) Source specificity of early calcium neurotoxicity in cultured embryonic spinal neurons. J. Neurosci. 13, 2085 2104.
40. Valerie K., Yacoub A., Hagan M. P., Curiel D. T., Fisher P. B., Grant S. Dent P. (2007) Radiation-induced cell signaling: inside-out and outside-in. Mol. Cancer Ther. 6, 789 801.
41. Weissman L., de Souza-Pinto N. C., Stevnsner T. Bohr V. A. (2007) DNA repair mitochondria and neurodegeneration. Neuroscience 145, 1318 1329.
42. Wu J., Lau L. F. Sturgill T. W. (1994) Rapid deactivation of MAP kinase in PC12 cells occurs independently of induction of phosphatase MKP-1. FEBS Lett. 353, 9 12.